Trevi Therapeutics (TRVI) Research & Development (2018 - 2025)
Trevi Therapeutics' quarterly Research & Development came in at $6.2 million in Q4 2025, down 33.61% year-on-year from $9.3 million in Q4 2024, and down 38.59% quarter-over-quarter from $10.1 million in Q3 2025.
Trevi Therapeutics has reported Research & Development for 8 years, with the latest figure at $6.2 million in Q4 2025.
- For the quarter ending Q4 2025, Research & Development fell 33.61% year-over-year to $6.2 million; the trailing twelve-month figure through Dec 2025 stood at $35.0 million (down 11.13% YoY), and the FY2025 full-year result was $33.5 million, down 14.98% from the prior year.
- Research & Development for Q4 2025 stood at $6.2 million, down from $10.1 million in the prior quarter.
- The five-year high for Research & Development was $11.2 million in Q3 2024, with the low at $4.3 million in Q4 2022.
- Average Research & Development over 5 years is $6.9 million, with a median of $6.2 million recorded in 2025.
- Year-over-year, Research & Development surged 77.51% in 2024 and sank 33.61% in 2025.
- Tracing TRVI's Research & Development over 5 years: stood at $6.2 million in 2021, then tumbled by 30.13% to $4.3 million in 2022, then jumped by 50.98% to $6.5 million in 2023, then jumped by 43.11% to $9.3 million in 2024, then sank by 33.61% to $6.2 million in 2025.
- The last three Research & Development figures came in at $6.2 million (Q4 2025), $10.1 million (Q3 2025), and $9.4 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.19 Mn |
| Sep 30, 2025 | 10.09 Mn |
| Jun 30, 2025 | 9.39 Mn |
| Dec 31, 2024 | 9.33 Mn |
| Sep 30, 2024 | 11.22 Mn |
| Jun 30, 2024 | 10.02 Mn |
| Mar 31, 2024 | 8.80 Mn |
| Dec 31, 2023 | 6.52 Mn |
| Sep 30, 2023 | 6.32 Mn |
| Jun 30, 2023 | 5.84 Mn |
| Mar 31, 2023 | 5.00 Mn |
| Dec 31, 2022 | 4.32 Mn |
| Sep 30, 2022 | 5.77 Mn |
| Jun 30, 2022 | 5.10 Mn |
| Mar 31, 2022 | 4.65 Mn |
| Dec 31, 2021 | 6.18 Mn |
| Sep 30, 2021 | 4.72 Mn |
| Jun 30, 2021 | 6.50 Mn |
| Mar 31, 2021 | 5.59 Mn |
| Dec 31, 2020 | 6.56 Mn |
| Sep 30, 2020 | 4.83 Mn |
| Jun 30, 2020 | 4.92 Mn |
| Mar 31, 2020 | 6.02 Mn |
| Dec 31, 2019 | 4.82 Mn |
| Sep 30, 2019 | 5.65 Mn |
| Jun 30, 2019 | 5.53 Mn |
| Mar 31, 2019 | 3.34 Mn |
| Dec 31, 2018 | 4.52 Mn |
| Sep 30, 2018 | 3.75 Mn |
| Jun 30, 2018 | 3.44 Mn |
| Mar 31, 2018 | 2.36 Mn |